Document is current
Any future updates will be listed below
-
Authors
Gon, Yasuhiro https://orcid.org/0000-0003-0514-3054
Sorimachi, Ryoko
Yoshida, Yuri
Tamai, Yoichi
Takashima, Ikumi
Arita, Yoshifumi
Sugiura, Hisatoshi https://orcid.org/0000-0002-4335-7048
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05903989 at ClinicalTrials.govDocuments that mention this clinical trial
Real-World Treatment Patterns and Patient-Reported Outcomes in Chronic Obstructive Pulmonary Disease in Japan: The REMIND Study
https://doi.org/10.1007/s12325-024-02927-5
-
Funding
Funding for this research was provided by:
AstraZeneca K.K.
- License Information
-
More Information
Article History
Received: 25 April 2024
Accepted: 12 June 2024
First Online: 24 July 2024
Declarations
:
: Yasuhiro Gon has received grants from GSK, AstraZeneca, and Novartis; has received honoraria from AstraZeneca, GSK, and Sanofi; and has received payment for expert testimony from AstraZeneca and GSK. Ryoko Sorimachi, Yuri Yoshida, Yoichi Tamai, Ikumi Takashima, and Yoshifumi Arita are employees of AstraZeneca K.K. Hisatoshi Sugiura has received consulting fees from AstraZeneca; and honoraria from AstraZeneca, Novartis, Boehringer Ingelheim, and GSK.
: The COPD Cohort Study was conducted in adherence to the Declaration of Helsinki and applicable local and international guidelines for medical and health research involving human participants. The study was approved by the Ethics Committee of Tohoku University Hospital (approval reference number 2018-2-147-1). All participants gave informed consent prior to registration in the COPD Cohort Study, and medical data were collected and stored in compliance with the relevant laws/regulations concerning data protection and the Personal Information Protection Act. Permission was sought for use of data from each site that participated in the COPD Cohort Study; the REMIND study only included data from sites that explicitly granted permission for reuse. The REMIND study was approved by the NPO-MINS Institutional Review Board (approval number 230215, June 2023) and registered at ClinicalTrials.gov (NCT05903989).
